Skip to content

HAART patients at greater risk of severe side-effects than AIDS

WHO unveils plans to treat 3 million by 2005

d4T/3TC/nevirapine will be preferred option for 3 x 5

Community mobilisation key to success of 3 x 5

India to begin free HIV treatment programme, will treat 100,000 within a year

HIV testing in Africa: will VCT for all do more than ABC approach?

Treatment with HAART reduces liver-related mortality in HIV/HCV coinfected patients

Tipranavir now available for emergency use in UK

Gastrointestinal side-effects lead one in eight to change HAART regimen in first year of treatment